We are happy to share our latest research findings: ‘Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying antirheumatic drugs: does line of therapy matter?’

This analysis, performed by Dr Kim Lauper, looks into the incidence of serious infections and active tuberculosis among seven biological DMARDs in rheumatoid arthritis patients using data from 33,897 patients in the BSRBR-RA study.

Key Take-aways

1. The risk of serious infections remains consistent across therapy lines.
2. Tuberculosis risk is notably higher in the early treatment phases or before 2009.
3. When comparing the effects of treatments on events, it’s essential to account for the line of therapy and/or the year of treatment initiation, especially for conditions such as TB, where management has undergone significant changes over time.

Read the full paper in the journal Rheumatology.

Related